On May 22, 2019 Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) reported that on May 21, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting in 2015 (the "2015 HCML Share Option Scheme") (Press release, Hutchison China MediTech, MAY 22, 2019, https://www.chi-med.com/grant-of-share-options-under-share-option-scheme/ [SID1234556762]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chi-Med granted 18,000 share options under its 2015 HCML Share Option Scheme to certain employees to subscribe for Ordinary Shares subject to the acceptance of the grantees. Details of such share options granted prescribed are as follows:

Date of grant: May 21, 2019

Exercise price of share options granted: GBP42.20 per Ordinary Share

Number of share options granted: 18,000 (each share option shall entitle the holder thereof to subscribe for one Ordinary Share)

Closing market price of Ordinary Shares on the date of grant: GBP42.20 per Ordinary Share

Validity period of the share options: From May 21, 2019 to May 20, 2029